What is FathomX?
Originating as a high-impact spin-off from the National University of Singapore and the National University Health System, FathomX operates at the intersection of deep learning and radiology. The company's flagship innovation, FxMammo, serves as a sophisticated AI assistant engineered to augment the accuracy of mammogram screenings. By systematically reducing the incidence of false positives and negatives, FathomX addresses critical bottlenecks in diagnostic workflows. As a key participant in the MedTech JUMPStart Program, the firm leverages institutional research rigor to deliver scalable, evidence-based healthcare technology that meets the rising demand for advanced screening tools in the Asia Pacific region.
How much funding has FathomX raised?
FathomX has raised a total of $1.6M across 1 funding round:
Other Financing Round
$1.6M
Other Financing Round (2022): $1.6M, investors not publicly disclosed
Key Investors in FathomX
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for FathomX?
With the recent capital deployment, FathomX is poised to transition from a research-backed entity to a dominant player in the enterprise-level digital health market. The strategic roadmap focuses on scaling the FxMammo platform to integrate seamlessly into diverse clinical environments, thereby optimizing diagnostic throughput and patient outcomes. Future growth initiatives will likely prioritize regulatory expansion and the development of additional AI-driven diagnostic modules. By capitalizing on its strong academic foundations and the current momentum in the MedTech sector, FathomX is set to redefine the standard of care in breast cancer screening, ensuring that advanced diagnostic capabilities are accessible and efficient for healthcare providers across its target markets.
See full FathomX company page
